^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CLDN6-targeted antibody-drug conjugate

    Related drugs:
    17d
    Discovery of Kinesin KIF18A Inhibitor ATX020: Tactical Application of Silicon Atom Replacement. (PubMed, ACS Med Chem Lett)
    ATX020 is a potent KIF18A inhibitor with a high degree of kinesin selectivity, favorable in vitro and in vivo ADME properties, and robust efficacy in the OVCAR-3 cell-derived xenograft (CDX) model. A high-resolution crystal structure of the KIF18A-tubulin complex and an experimentally guided model of ATX020 bound to the complex are provided, supporting future structure-based drug design of KIF18A inhibitors.
    Journal
    |
    KIF18A (Kinesin Family Member 18A)
    4ms
    FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=83, Not yet recruiting, Axcynsis Therapeutics Pte Ltd | Initiation date: Aug 2025 --> Nov 2025
    Trial initiation date
    5ms
    Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusion. (PubMed, Am J Ophthalmol Case Rep)
    Collagen and silicone punctal plugs were placed and the patient was started on preservative free artificial tears, topical loteprednol 0.5 %, later replaced with topical prednisolone acetate 1 % drops, and brimonidine 0.2 % in both eyes. Ocular symptoms and exam findings waxed and waned with continued infusions of the ADC. This case reports an incidence of corneal pseudomicrocysts associated with TORL-1-23 treatment, which should be recognized as a potential adverse effect of this novel therapy.
    Journal
    |
    CLDN6 (Claudin 6)
    |
    ixotatug vedotin (TORL-1-23)
    5ms
    REFMAL 823: A Study of DS-9606a in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=88, Active, not recruiting, Daiichi Sankyo | Recruiting --> Active, not recruiting
    Enrollment closed
    7ms
    TRIO-049: First in Human Study of TORL-1-23 in Participants With Advanced Cancer (clinicaltrials.gov)
    P1, N=90, Recruiting, TORL Biotherapeutics, LLC | Trial primary completion date: Apr 2025 --> Aug 2026 | Trial completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    ixotatug vedotin (TORL-1-23)
    8ms
    Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=256, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1 trial
    9ms
    TRIO-049: First in Human Study of TORL-1-23 in Participants with Advanced Cancer (clinicaltrials.gov)
    P1, N=90, Recruiting, TORL Biotherapeutics, LLC | Trial primary completion date: Nov 2024 --> Apr 2025
    Trial primary completion date
    |
    ixotatug vedotin (TORL-1-23)
    10ms
    FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=78, Not yet recruiting, Axcynsis Therapeutics Pte Ltd
    New P1 trial
    1year
    TORL123-002: CATALINA-2: a Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. (clinicaltrials.gov)
    P2, N=230, Recruiting, TORL Biotherapeutics, LLC | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    CLDN6 (Claudin 6) • PROC (Protein C, Inactivator Of Coagulation Factors Va And VIIIa)
    |
    ixotatug vedotin (TORL-1-23) • Neulasta (pegfilgrastim)
    1year
    CATALINA-2: a Phase 2 Study of TORL-1-23 in Advanced Ovarian Cancer. (clinicaltrials.gov)
    P2, N=230, Not yet recruiting, TORL Biotherapeutics, LLC
    New P2 trial • Metastases
    |
    CLDN6 (Claudin 6) • PROC (Protein C, Inactivator Of Coagulation Factors Va And VIIIa)
    |
    CLDN6 expression
    |
    ixotatug vedotin (TORL-1-23) • Neulasta (pegfilgrastim)
    over1year
    A Study of DS-9606a in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=85, Recruiting, Daiichi Sankyo | N=125 --> 85
    Enrollment change
    almost2years
    A Study of DS-9606a in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=125, Recruiting, Daiichi Sankyo, Inc. | Trial completion date: Nov 2023 --> Feb 2026 | Trial primary completion date: Nov 2023 --> Feb 2026
    Trial completion date • Trial primary completion date • Metastases